ストックスクリーナーアプリを入手
3.9601
1.00%
-0.0399
アフターアワーズ：
3.95
-0.0101
-0.26%
前日終値:
$4.00
開ける：
$4.01
24時間の取引高:
38,668
Relative Volume:
0.97
時価総額：
$10.70M
収益：
-
当期純損益:
$-10.69M
株価収益率:
-0.5592
EPS:
-7.0818
ネットキャッシュフロー:
$-9.07M
1週間 パフォーマンス:
-4.81%
1か月 パフォーマンス:
-18.68%
6か月 パフォーマンス:
-36.69%
1年 パフォーマンス:
-46.93%
1日の値動き範囲:
$3.9008
$4.19
1週間の範囲:
$3.9008
$4.35
52週間の値動き範囲:
$3.51
$43.50
Intensity Therapeutics Inc Stock (INTS) Company Profile
名前
Intensity Therapeutics Inc
セクター
電話
203-221-7381
住所
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
3.9601 | 11.24M | 0 | -10.69M | -9.07M | -7.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Intensity Therapeutics Inc (INTS) 最新ニュース
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript - aol.com
Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
Intensity Therapeutics Warns of Substantial Doubt - Minichart
Intensity Therapeutics Q2 Results: EPS loss narrows 67% YoY - scanx.trade
INTS: Q2 2026 saw higher R&D spend, resumed trial enrollment, and strong early TNBC efficacy data - TradingView
Transcript : Intensity Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Form 8K Intensity Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
INTS: Net loss rose 19% to $3M as clinical trials resumed, with $9.5M cash and $30M more needed for completion - TradingView
Earnings call transcript: Intensity Therapeutics misses Q2 2026 EPS as shares slip premarket - Investing.com
Intensity Therapeutics (INTS) Advances Clinical Trials Amidst Ch - GuruFocus
Intensity Therapeutics Reports $3.0 Million Q2 Net Loss - Quiver Quantitative
Intensity Therapeutics reports Q2 2026 net loss of $3.0M, cash $9.5M; resumes select trial enrollment - TradingView
Intensity Therapeutics Q2 net loss widens as R&D costs rise - TradingView
INTS: Resumed clinical trial enrollment and raised capital, with improved early TNBC study results - TradingView
BRIEF-Intensity Therapeutics Q2 Operating Income USD -3.084 Million - TradingView
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary - TradingView
INTS Q2'26 Earnings: EPS estimate is (0.87) USD - TradingView
BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million - TradingView
Intensity Therapeutics (INTS.US) will release its earnings report on August 11. - Moomoo
Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intensity Therapeutics Inc (INTS) Stock News Today - TradingKey
Intensity Therapeutics (INTS.US) will release its earnings report before the market opens on August 11. - Moomoo
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 - Yahoo Finance
INTS Q2'26 Earnings: revenue estimate is 0 USD - TradingView
INTS|Intensity Therapeutics Inc|Price:4.570|Chg%:+0.120 - TradingKey
INTS|Intensity Therapeutics Inc|Price:3.960|Chg%:-0.040 - TradingKey
Intensity Therapeutics Inc (INTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Intensity Therapeutics Inc (INTS) Balance Sheet - TradingKey
Intensity Therapeutics Inc (INTS) Income Statement - TradingKey
Intensity Therapeutics Inc (INTS) Cash Flow - TradingKey
INTS|Intensity Therapeutics Inc|Price:4.450|Chg%:+0.030 - TradingKey
INTS Stock Price, Quote & Chart - ChartMill
Intensity Therapeutics (INTS) Proxy filing Summary - Quartr
Intensity Therapeutics (INTS) Q1 2026 earnings summary - Quartr
Director Mark Goldberg awarded 5,500 options at Intensity Therapeutics (INTS) - Stock Titan
Intensity Therapeutics (INTS) awards director 5,500 options at $4.90 strike - Stock Titan
Intensity Therapeutics grants 5,500-share option to director | INTS Insider Trading - Stock Titan
Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90 - Stock Titan
Intensity Therapeutics (INTS) grants 11,000 stock options to accounting officer - Stock Titan
Intensity Therapeutics (INTS) awards CFO 34,000 stock options at $4.90 - Stock Titan
Intensity Therapeutics grants 78,000 options to CEO | INTS Insider Trading - Stock Titan
Intensity Therapeutics Restarts Phase 2 TNBC Trial - t.co
Intensity Therapeutics (INTS) Edges Higher, Holding Above Key Support at $4.66Fear Greed Extreme - dars.gov.et
New patients dosed with INT230-6 in Swiss trial for aggressive triple-negative breast cancer - Pluang
Intensity Therapeutics (INTS) AGM 2026 Summary - Quartr
Intensity Therapeutics (INTS) Q4 2025 earnings summary - Quartr
Intensity Therapeutics restarts 61-patient breast cancer trial - grafa.com
Intensity Therapeutics Inc (INTS) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):